Pacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $3.00 by Analysts at Barclays
The Cerbat Gem - 2024-04-10T16:20:42.000Z

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its target price dropped by investment analysts at Barclays from $8.00 to $3.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price objective suggests a potential downside of 10.18% from the […] Read this story